+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Generalized Anxiety Disorder - Pipeline Insight, 2020

  • ID: 5215133
  • Drug Pipelines
  • December 2020
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Avinueuro Pharmaceuticals
  • MORE
This “Generalized Anxiety Disorder - Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Generalized Anxiety Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Generalized Anxiety Disorder Understanding

Generalized Anxiety Disorder: Overview

Generalized anxiety disorder (GAD) is a common and disabling illness that is often underdiagnosed and undertreated. GAD is characterized by at least 6 months of persistent and excessive anxiety. Patients with GAD are at increased risk for suicide as well as cardiovascular-related events and death. Most patients can be diagnosed and managed by primary care physicians. Having low socioeconomic status; being widowed, separated, or divorced; or being middle-aged increases risk for GAD. Additional risk factors include comorbid psychiatric disorders, history of substance abuse or trauma, and family history of GAD.

Symptoms

The symptoms of Generalized Anxiety Disorder include:
  • Chronic, pervasive anxiety and worry accompanied by nonspecific physical and psychological symptoms (restlessness, fatigue, difficulty concentrating, irritability, muscle tension, or sleep disturbances).
Diagnosis

When evaluating patients for GAD, clinicians should consider medical conditions (for example, cardiac, pulmonary, or endocrine illnesses), mood and other anxiety disorders, adverse effects of prescribed or over-the-counter medications and supplements, and substance misuse and withdrawal. Several physical and mental disorders can mimic or co-occur with GAD. Most patients with GAD can be diagnosed by a primary care physician. However, in cases of diagnostic uncertainty or multiple comorbid mental health conditions, clinicians should consider obtaining a second opinion from a psychologist, psychiatrist, or other mental health specialist.

Treatment

Cognitive behavioral therapy (CBT) is to identify and change unhelpful thoughts and behaviors to improve emotions and quality of life. Some CBT techniques, especially exposure therapy, may temporarily increase distress but eventually lead to reduction in chronic anxiety. Types of exposure therapy include imaginal (vividly imagining the feared object, situation, or activity), in vivo (directly facing a feared object, situation, or activity in real life), and interoceptive (deliberately bringing on physical sensations that are harmless but feared). Other commonly used techniques in CBT include education; goal setting; selfmonitoring; cognitive restructuring; relaxation training, including biofeedback; and problem solving. Clinicians should offer drug therapy if nondrug therapies are ineffective or the patient is not interested in them. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are recommended as first-line drug therapies because of their tolerability and efficacy compared with other drug therapies.

Generalized Anxiety Disorder Emerging Drugs Chapters

This segment of the Generalized Anxiety Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Generalized Anxiety Disorder Emerging Drugs

FKW00GA: Fabre-Kramer Pharmaceuticals

FKW00GA is unique in that it will be the first 5HT1A Agonist and 5HT2 Antagonist on the market for the treatment of anxiety. FKW00GA is in Phase 2 of development and is being developed by Fabre-Kramer Pharmaceuticals. Preclinical studies have shown it to have a very high affinity for the serotonin 1A (5HT1A) receptor. In addition, FKW00GA has a high affinity for the serotonin 2 (5HT2) receptor.

Generalized Anxiety Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Generalized Anxiety Disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Generalized Anxiety Disorder

There are approx. 10+ key companies which are developing the therapies for Generalized Anxiety Disorder. The companies which have their Generalized Anxiety Disorder drug candidates in the most advanced stage, i.e. phase II include, Fabre-Kramer Pharmaceuticals.

Phases

This report covers around 10+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Generalized Anxiety Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Generalized Anxiety Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Generalized Anxiety Disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Generalized Anxiety Disorder drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Generalized Anxiety Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Generalized Anxiety Disorder.
Generalized Anxiety Disorder Report Insights
  • Generalized Anxiety Disorder Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Generalized Anxiety Disorder Disease Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Generalized Anxiety Disorder drugs?
  • How many Generalized Anxiety Disorder drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Generalized Anxiety Disorder?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Generalized Anxiety Disorder therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Generalized Anxiety Disorder and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Avinueuro Pharmaceuticals
  • Fabre-Kramer Pharmaceuticals
Key Products
  • AVN101
  • FKW00GA

This report will be delivered within 1-3 business days
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Avinueuro Pharmaceuticals
  • MORE
Introduction

Executive Summary

Generalized Anxiety Disorder: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Generalized Anxiety Disorder- Analytical Perspective

In-depth Commercial Assessment
  • Generalized Anxiety Disorder Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Generalized Anxiety Disorder Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
FKW00GA: Fabre-Kramer Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Generalized Anxiety Disorder Key Companies

Generalized Anxiety Disorder Key Products

Generalized Anxiety Disorder- Unmet Needs

Generalized Anxiety Disorder- Market Drivers and Barriers

Generalized Anxiety Disorder- Future Perspectives and Conclusion

Generalized Anxiety Disorder Analyst Views

Generalized Anxiety Disorder Key Companies

Appendix

List of Tables
Table 1 Total Products for Generalized Anxiety Disorder
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Generalized Anxiety Disorder
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
3 of 3
  • Avinueuro Pharmaceuticals
  • Fabre-Kramer Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll